Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Alcon pairs 5% Q3 sales growth with a Neurotech purchase as eye-care dealmaking widens

Alcon announced its planned Neurotech Pharmaceuticals acquisition alongside $2.7bn in third-quarter sales, while smaller biotechs show the range of exits and funding routes now in play.

15 Nov 2026 · CompePharma editorial

What happened

Alcon reported third-quarter sales up 5% to $2.7bn and nine-month sales of $8.2bn. The company attributed growth to dry eye products and surgical equipment launches. In the same update it highlighted its planned purchase of Neurotech Pharmaceuticals.

The material available to us does not include the purchase price, the structure, the expected closing timetable, or details of Neurotech's assets or financials. Any assessment of valuation or accretion is therefore premature. What can be analysed is the context: the timing, the commercial base Alcon is building from, and how the deal sits against other eye-care and small-cap transactions this week.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →